Non-small cell carcinoma
Information
- Disease name
- Non-small cell carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04364048 | Active, not recruiting | Phase 2 | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | June 18, 2020 | December 31, 2024 |
| NCT05551117 | Active, not recruiting | Phase 2 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | June 13, 2023 | May 2027 |
| NCT04791839 | Active, not recruiting | Phase 2 | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | August 4, 2021 | April 30, 2029 |
| NCT00073398 | Completed | Phase 1/Phase 2 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | November 2003 | March 2013 |
| NCT03394105 | Completed | Phase 2 | Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer | July 26, 2016 | June 22, 2018 |
| NCT05451173 | Not yet recruiting | Phase 1/Phase 2 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | October 9, 2023 | December 31, 2025 |
| NCT06057766 | Recruiting | N/A | Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer | January 1, 2024 | June 1, 2025 |
| NCT02922764 | Recruiting | Phase 1 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | November 2016 | May 2024 |
| NCT03991819 | Recruiting | Phase 1 | Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer | September 20, 2019 | December 2026 |
| NCT04171492 | Recruiting | Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules | December 18, 2020 | December 2026 | |
| NCT05319886 | Recruiting | Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients | May 16, 2022 | March 30, 2025 | |
| NCT05752552 | Recruiting | Phase 1 | Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours | December 20, 2022 | April 2025 |
| NCT05919264 | Recruiting | Phase 1/Phase 2 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | May 19, 2023 | August 31, 2027 |
| NCT05973487 | Recruiting | Phase 1 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | May 6, 2024 | December 30, 2026 |
| NCT05569291 | Recruiting | N/A | Investigating the Feasibility of a Physical Activity (Tele)Coaching Intervention in Patients With Non-small Cell Lung Cancer: an Explorative Study | October 1, 2022 | December 1, 2023 |
| NCT05657873 | Recruiting | Phase 2 | A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | December 9, 2022 | December 9, 2025 |
| NCT02376699 | Terminated | Phase 1 | Safety Study of SEA-CD40 in Cancer Patients | February 28, 2015 | April 14, 2023 |
| NCT04695925 | Unknown status | Phase 3 | Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations | January 4, 2021 | December 30, 2023 |
| NCT05007769 | Withdrawn | Phase 2 | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | October 31, 2021 | April 30, 2026 |